Cell Signaling · Skim version

Antigen Receptors and Checkpoints

About 1 min to skim · 3 figures

Read the full lesson → Skim the whole course →

The guiding idea

The T-cell receptor has no enzyme and almost no tail. How does it tell the cell to kill?

How does a receptor with no enzyme and almost no tail switch on a T cell, and what keeps that cell from attacking healthy tissue?

  1. The idea: one set of chains recognises, another set signals

  2. The first minute: two phosphates, then three branches

    AI-generated illustration: two membranes, the presenting cell above and the T cell below. The receptor reads a peptide held on an MHC protein, and a co-receptor beside it grips the same MHC protein and carries Lck on its inner tail. On one partner-chain tail inside the T cell, an ITAM carries two phosphates, and the two lobes of ZAP-70 grip both phosphates of that one ITAM. An arrow runs from ZAP-70 to the LAT scaffold in the membrane, from which three arrows fan out to calcium, DAG and Ras.
    The receptor carries no enzyme. Lck, riding on a co-receptor that grips the same MHC protein, phosphorylates both tyrosines of an ITAM; ZAP-70 binds tightly only when both are phosphorylated, then phosphorylates the LAT scaffold, from which three branches leave: calcium, DAG and Ras. AI-generated illustration
  3. One signal is not enough: the second signal and two brakes

    AI-generated illustration: two panels, each a T cell facing a presenting cell. On the left, the T-cell receptor binds a peptide held on an MHC protein while CD28 has no partner, and the outcome box reads Anergy. On the right, CD28 also grips B7 on the presenting cell, two arrows run into the T cell, and the outcome box reads Activation.
    For a T cell meeting its antigen for the first time, signal one from the receptor is not trusted alone. CD28 must also bind a B7 protein, which presenting cells display once they have detected signs of infection. In the classic cultured-cell experiments, signal one alone left the cell in the lasting unresponsive state called anergy. AI-generated illustration
    AI-generated illustration: two schematic panels, titled CTLA-4: outside and PD-1: inside, each showing a T cell below a presenting cell. Left, CTLA-4 on the T cell reaches up and grips two B7 proteins on the presenting cell, while CD28, labelled weaker grip, reaches toward one B7 with a dotted line. Right, PD-1 on the T cell is bound to PD-L1 on another cell and has two phosphate circles on its tail; the phosphatase SHP-2 docks on those phosphates, and an arrow runs from SHP-2 to a phosphate on the tail of CD28, which is bound to B7 beside it, labelled SHP-2 removes CD28's phosphate.
    Two brakes, simplified. CTLA-4 binds B7 more tightly than CD28 does and can remove it from presenting cells, reducing co-stimulation; regulatory T cells use this route. PD-1 brakes from inside: once PD-L1 binds, its phosphorylated tail, mainly the ITSM motif, recruits the phosphatase SHP-2, which removes phosphates from activating signalling proteins such as CD28 and components of the antigen-receptor pathway. The tail phosphates themselves are the docking site, not the target. AI-generated illustration
  4. Releasing a brake to treat cancer

  5. Building a receptor from parts

Read the full lesson → Skim the whole course →